PL378108A1 - Leczenie łączone do terapii zapalnych zaburzeń immunologicznych - Google Patents

Leczenie łączone do terapii zapalnych zaburzeń immunologicznych

Info

Publication number
PL378108A1
PL378108A1 PL378108A PL37810804A PL378108A1 PL 378108 A1 PL378108 A1 PL 378108A1 PL 378108 A PL378108 A PL 378108A PL 37810804 A PL37810804 A PL 37810804A PL 378108 A1 PL378108 A1 PL 378108A1
Authority
PL
Poland
Prior art keywords
treatment
combination therapy
immunoinflammatory disorders
immunoinflammatory
disorders
Prior art date
Application number
PL378108A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Bradley B. Brasher
Todd W. Chappel
Palaniyandi Manivasakam
Noah Sachs
Brendan Smith
Benjamin A. Auspitz
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of PL378108A1 publication Critical patent/PL378108A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
PL378108A 2003-02-14 2004-02-12 Leczenie łączone do terapii zapalnych zaburzeń immunologicznych PL378108A1 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US44764803P 2003-02-14 2003-02-14
US44755303P 2003-02-14 2003-02-14
US44736603P 2003-02-14 2003-02-14
US44741203P 2003-02-14 2003-02-14
US44741503P 2003-02-14 2003-02-14
US46475303P 2003-04-23 2003-04-23
US50302603P 2003-09-15 2003-09-15

Publications (1)

Publication Number Publication Date
PL378108A1 true PL378108A1 (pl) 2006-03-06

Family

ID=32913413

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378108A PL378108A1 (pl) 2003-02-14 2004-02-12 Leczenie łączone do terapii zapalnych zaburzeń immunologicznych

Country Status (14)

Country Link
US (1) US20040224876A1 (pl)
EP (1) EP1599212A4 (pl)
JP (1) JP2006517969A (pl)
KR (1) KR20050110634A (pl)
AR (1) AR043188A1 (pl)
AU (1) AU2004212919A1 (pl)
CA (1) CA2514061A1 (pl)
HR (1) HRP20050804A2 (pl)
IS (1) IS8023A (pl)
MX (1) MXPA05008649A (pl)
NO (1) NO20053678L (pl)
PL (1) PL378108A1 (pl)
TW (2) TW200902047A (pl)
WO (1) WO2004073614A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812110D0 (en) 1998-06-06 1998-08-05 Levelrecall Limited Yttrium oxide based gas mantle
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005053665A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ice inhibitors
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
SI1719507T1 (sl) 2005-04-13 2010-11-30 Astion Dev As Beta adrenoceptor agonisti za zdravljenje bolezni veznega tkiva kože
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
US20060293381A1 (en) * 2005-06-23 2006-12-28 Kaihei Kojima Fungicidal effect by regulating signal transduction pathways
ITMI20051826A1 (it) * 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
WO2007041677A2 (en) * 2005-10-03 2007-04-12 Combinatorx, Incorporated Soft tissue implants and drug combination compositions, and use thereof
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
JP2009523029A (ja) * 2006-01-10 2009-06-18 コルゲート・パーモリブ・カンパニー 炎症の予防または軽減のために、細胞表面受容体を調節する方法
AU2011205053B2 (en) * 2006-02-02 2013-02-07 Novartis Ag Tuberous Sclerosis treatment
PT1983984T (pt) 2006-02-02 2018-06-14 Novartis Ag Tratamento da esclerosa tuberosa
US8207188B2 (en) * 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
CN101568331A (zh) * 2006-09-08 2009-10-28 奥尔制药有限公司 减少或缓解消化道炎症的方法
EP2170317A4 (en) * 2007-02-12 2011-03-23 Mike Nicolaou TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN
KR101519028B1 (ko) * 2007-04-13 2015-05-11 써던 리서취 인스티튜트 항혈관형성제 및 사용방법
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
TW200927102A (en) * 2007-09-18 2009-07-01 Univ Stanford Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
US8975247B2 (en) * 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
AU2009343748B2 (en) 2009-04-01 2013-01-31 Colgate-Palmolive Company Anti-biofilm carbonate compounds for use in oral care compositions
US10426752B2 (en) 2009-04-01 2019-10-01 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents
AR076177A1 (es) 2009-04-01 2011-05-26 Colgate Palmolive Co MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
TWI481870B (zh) 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記
KR101388235B1 (ko) * 2011-09-20 2014-04-24 가톨릭대학교 산학협력단 메클리진을 포함하는 관절염 예방 및 치료용 조성물
TWI881480B (zh) 2015-06-30 2025-04-21 美商伊格集團國際股份有限公司 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
KR102422449B1 (ko) * 2019-10-18 2022-07-20 연세대학교 산학협력단 결핵 및 비결핵항산균 감염 질환의 예방, 개선 또는 치료용 조성물
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101104A (en) * 1965-06-02 1968-01-31 Joseph Glasser Compositions for the treatment of psoriasis
US4444780A (en) * 1982-08-30 1984-04-24 Ortho Pharmaceutical Corporation Method for treating atopic dermatitis
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
ES2184808T3 (es) * 1994-10-05 2003-04-16 Cari Loder Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
FI104363B (fi) * 1997-05-19 2000-01-14 Timo Kalevi Korpela Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
HUP0002296A3 (en) * 1997-07-01 2001-11-28 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
IN188720B (pl) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
AU3126700A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP2004510694A (ja) * 2000-05-08 2004-04-08 ヘインズ　デイビッド 免疫抑制性組成物
AU2001296542B2 (en) * 2000-10-02 2007-10-25 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
HRP20050355A2 (en) * 2002-09-24 2005-10-31 Combinatorx Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
KR20060076319A (ko) * 2003-09-24 2006-07-04 콤비네이토릭스, 인코포레이티드 약물 조합들을 투여하는 치료 요법

Also Published As

Publication number Publication date
AU2004212919A1 (en) 2004-09-02
AR043188A1 (es) 2005-07-20
JP2006517969A (ja) 2006-08-03
WO2004073614A2 (en) 2004-09-02
KR20050110634A (ko) 2005-11-23
NO20053678L (no) 2005-09-12
WO2004073614A3 (en) 2004-11-11
TW200509958A (en) 2005-03-16
MXPA05008649A (es) 2005-11-23
HRP20050804A2 (en) 2006-02-28
CA2514061A1 (en) 2004-09-02
TW200902047A (en) 2009-01-16
NO20053678D0 (no) 2005-07-29
US20040224876A1 (en) 2004-11-11
EP1599212A4 (en) 2006-02-08
IS8023A (is) 2005-09-13
EP1599212A2 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
SI1660057T1 (sl) Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2003286567A8 (en) Methods for the treatment of skin disorders
GB0316912D0 (en) Therapeutic treatment
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
GB0320806D0 (en) Therapeutic treatment
IL173351A0 (en) Therapy of ocular disorders
GB0223367D0 (en) Therapeutic treatment
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
GB0213869D0 (en) The treatment of pain
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
GB0223854D0 (en) Therapeutic treatment
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0329275D0 (en) Therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)